Braintale, a medtech spin-off from Paris Region Greater Hospital, specializes in the often-underestimated field of white matter within neurosciences. The company, positioned at the forefront of innovation, is ushering in a new medical era. Braintale focuses on furnishing physicians with clinically validated diagnostic, monitoring, and predictive solutions for managing patients with brain injuries. This is achieved through precise and reliable measurements of alterations in white-matter microstructure. The BrainTale-care platform facilitates a quantitative and standardized evaluation of deep white matter integrity to enhance brain care. Utilizing diffusion magnetic resonance imaging, these biomarkers offer non-invasive measurements, delivering sensitive and reliable assessments of white matter alterations.